Company: VRCA
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001193125-25-087838
Chunk: 57

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 57
---
 |     |                                                                | 1,047,596 |     |                                                                                         |  437,433 |   |     |                                                                    | 299,750 |     |                                                                                                                    |  400,251 |   |     |                                                                                              | —        |   |     |                                     |    476,836 |   |     |                      | 2,806,409 |   |
| 2022 |     |                                                         |   987,849 |     |                                                                  | (436,149   | ) |     |                                                                |    51,669 |     |                                                                                         | (680,104 | ) |     |                                                                    |       — |     |                                                                                                                    |  (76,756 | ) |     |                                                                                              | —        |   |     |                                     | (1,141,340 | ) |     |                      |  (153,491 | ) |

| (7) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our stock price at the end and the beginning of the measurement period by our stock price at the beginning of the measurement period. |

| (8) | The dollar amounts reported represent the amount of net loss reflected in our audited financial statements for the applicable year. |

Analysis of the Information Presented in the Pay Versus Performance Table As described in more detail above in “Executive Compensation” our executive compensation program reflects a performance-driven compensation philosophy. While we utilize several performance measures to align executive compensation with company performance, those company performance measures are not financial performance 43

measures and are therefore not presented in the PayVersus Performance table. Moreover, we generally seek to incentivize long-term performance, and therefore does not specifically align company performance measures with “compensation actually paid” (as computed in accordance with Item 402(v) of Regulation S-K)for a particular year. In accordance with Item 402(v) of Regulation S-K,we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table above. Compensation Actually Paid and Net Loss YCANTH, our first approved product, was approved by the U.S. Food and Drug Administration in July 2023. Accordingly, we did not generate substantial revenue from YCANTH during the periods presented. Because the majority of the revenue we recognized during the periods presented was associated with upfront and milestone payments under our license agreements, we do not use net loss